Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow | MicrobiomeTrials← Back to trialsNCT00330564
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2006-05Est. Completion: 2011-05
Enrollment target: 15 participants Locations- UT MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Borderline Personality Disorder (BPD)
This study is a mixed-methods, single-arm cross-sectional study comprising 1) a qualitative, exploratory, critical-const…
Heidelberg, GermanyEst. completion Dec 31, 2026
Retinal HemangioblastomaVon Hippel-Lindau Disease
Background:
Retinal hemangioblastoma (RH) is a tumor. It grows from the retina in the eye. It can threaten a person s v…
Bethesda, United StatesCompleted Jun 2, 2026
Recruiting
Von Hippel-Lindau DiseaseCarcinoma, Renal Cell
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors:
* Advan…
Boston, United StatesEst. completion Jan 14, 2034